Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Negrar
Clinical trial register · Italy

Clinical Trials in Negrar, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Italy and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6788 matching records held by the registry are in this view. Synced 13 Nov 2026, 03:19 UTC
6788
Studies in scope
all four open statuses
4077
Recruiting now
open to new participants
1016
Lead sponsors
across recruiting studies
Top sites
Milan 2855 Bologna 1282 Roma 1266 Naples 983 Rome 968
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
IRCCS Sacro Cuore Don Calabria di Negrar17 AbbVie9 Janssen Research & Development, LLC4 Eli Lilly and Company3 AstraZeneca2 Abivax S.A.2 Novartis Pharmaceuticals2 European Organisation for Research and Treatment of Cancer - EORTC2 Hoffmann-La Roche2 UMC Utrecht1 Spyre Therapeutics, Inc.1 Medtronic Cardiac Ablation Solutions1 NTC srl1 Fondazione Michelangelo1 Alfasigma S.p.A.1 Fondazione Ricerca Traslazionale1 Daiichi Sankyo1 Gilead Sciences1 Palisade Bio1 GlaxoSmithKline1 Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria1 Alimentiv Inc.1 Research Center Borstel1
Site location
Milan2855 Bologna1282 Roma1266 Naples983 Rome968 Florence788 Pavia573 Brescia523 Padova504 Genova490 Rozzano473 Bari451 Pisa401 Bergamo378 Meldola355 Catania340 Ancona298 Monza281 Verona281 Palermo277 Torino275 Modena259 Aviano201 Messina167 Alessandria164 Show all 490
All 490 locations
Target enrolment
to

Trials with a site in Negrar

57 of 6788 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Italy
Start
Active, closed
Evaluation of the Rapid Diagnostic Test SsRT+ for Strongyloides Stercoralis
NCT07876622Strongyloides Stercoralis Infection, Device Performance, Diagnostic
IRCCS Sacro Cuore Don Calabria di Negrar
Not applicable
780
Negrar
2026-10-02
Not yet open
Daiichi Sankyo
Phase 3
103
Milan, Naples, Negrar
2026-09-30
Recruiting
A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07845487Ulcerative Colitis (UC), Severe Ulcerative Colitis, Moderate Ulcerative Colitis
DrugPALI-2108
Palisade Bio
Phase 2
204
Bari, Bologna, Matera, Negrar, Rome, Rozzano, San Giovanni Rotondo, Turin
2026-08-28
Active, closed
Norovirus Prevalence and Fecal Microbiome Characterization Through Metagenomic and Metatranscriptomic Analyses
NCT07866469Microbiome, Metagenomic Next Generation Sequencing, Norovirus Infection
IRCCS Sacro Cuore Don Calabria di Negrar
Not applicable
100
Negrar
2026-07-28
Not yet open
Research Center Borstel
Observational
1,000
Negrar
2026-07
Recruiting
IRCCS Sacro Cuore Don Calabria di Negrar
Not applicable
6
Negrar
2026-06-09
By invitation
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD
NCT07652294Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
DrugsSPY001·SPY002·SPY003
Spyre Therapeutics, Inc.
Phase 2
645
Legnano, Negrar
2026-06-08
Recruiting
Janssen Research & Development, LLC
Phase 3
644
Milan, Negrar, Romagnano, Rozzano
2026-05-23
Recruiting
Janssen Research & Development, LLC
Phase 3
460
Milan, Negrar, Romagnano, Rozzano
2026-05-22
Recruiting
AstraZeneca
Phase 3
670
Milan, Misterbianco, Naples, Negrar, Reggio Emilia, Rozzano
2026-05-04
Recruiting
Eli Lilly and Company
Phase 2
60
Florence, Milan, Monza, Negrar, Roma, Rozzano
2026-05-04
Recruiting
Eli Lilly and Company
Phase 2
60
Florence, Milan, Monza, Negrar, Roma, Rozzano
2026-05-04
Active, closed
Diagnostic Performance and Acceptability of Rectal Swab for Screening of ESBL Enterobacterales
NCT07847606Enterobacteriaceae, Swabs, Beta Lactam Resistant Bacterial Infection
IRCCS Sacro Cuore Don Calabria di Negrar
Not applicable
300
Negrar
2026-01-12
Recruiting
IRCCS Sacro Cuore Don Calabria di Negrar
Not applicable
100
Negrar
2025-11-04
Recruiting
NTC srl
Phase 3
412
Carpi, Aviano, Negrar, Bologna, Brescia, Como, Milan, Roma
2025-09-02
Recruiting
Hoffmann-La Roche
Phase 3
425
Matera, Bologna, Rome, Brescia, Milan, San Donato Milanese (MI), Negrar
2025-05-12
Recruiting
European Organisation for Research and Treatment of Cancer - EORTC
Not applicable
302
Florence, Milan, Negrar, Roma, Torino
2025-04-15
Recruiting
IRCCS Sacro Cuore Don Calabria di Negrar
Not applicable
250
Negrar
2025-04-08
Recruiting
IRCCS Sacro Cuore Don Calabria di Negrar
Not applicable
96
Negrar
2025-02-20
Recruiting
Alimentiv Inc.
Not applicable
378
Castellana Grotte, Feltre, Florence, Milan, Negrar, Padova, Roma, Rome
2025-02-01
Recruiting
IRCCS Sacro Cuore Don Calabria di Negrar
Observational
30
Negrar
2024-12-19
Active, closed
Hoffmann-La Roche
Phase 3
350
Rome, Brescia, Milan, Monza MI, Rozzano (MI), Negrar
2024-12-11
Recruiting
Abivax S.A.
Phase 2
212
Bologna, Catanzaro, Milan, Negrar, Pavia, Roma, Rozzano, San Giovanni Rotondo
2024-10-30
Recruiting
AbbVie
Phase 2
590
Monserrato, San Giovanni Rotondo, Rozzano, Milan, Rome, Turin, Negrar, Catanzaro
2024-09-04
Active, closed
GlaxoSmithKline
Phase 3
10,212
Negrar, Alessandria, Bari, Belluno, Ferrara, Naples, Palermo, Pessione - Chieri to
2024-08-01
Recruiting
PulseSelect™ PFA Global Registry
NCT06393920Atrial Fibrillation
Medtronic Cardiac Ablation Solutions
Observational
1,950
Negrar, Ancona
2024-07-23
Recruiting
IRCCS Sacro Cuore Don Calabria di Negrar
Observational
402
Negrar
2024-07-10
Recruiting
IRCCS Sacro Cuore Don Calabria di Negrar
Not applicable
278
Bologna, Negrar, Florence
2024-06-28
Recruiting
IRCCS Sacro Cuore Don Calabria di Negrar
Not applicable
22
Negrar
2024-04-21
Recruiting
Efficacy of Robotic Upper Limb Rehabilitation Training in Patients With Tetraplegia
NCT07860827Tetraplegia/Tetraparesis, Rehabilitation Treatment, Gaining Skeletal Muscle Mass and Strength
IRCCS Sacro Cuore Don Calabria di Negrar
Not applicable
24
Negrar
2024-04-01
Active, closed
Gilead Sciences
Phase 2
228
Bologna, Cagliari, Catanzaro, Milan, Negrar, Padova, Palermo, Roma
2024-03-27
Recruiting
IRCCS Sacro Cuore Don Calabria di Negrar
Not applicable
384
Negrar
2024-03-25
Active, closed
AbbVie
Phase 2
156
Monserrato, Rome, Negrar
2024-03-23
Recruiting
IRCCS Sacro Cuore Don Calabria di Negrar
Not applicable
204
Negrar
2024-03-18
Recruiting
Novartis Pharmaceuticals
Phase 3
450
Brescia, Cona, Genova, Milan, Rozzano, Pisa, Roma, Negrar
2024-03-12
Active, closed
Alfasigma S.p.A.
Observational
509
Bari, Milan, Pisa, Negrar, Palermo, Rozzano, Torino
2023-06-12
Recruiting
IRCCS Sacro Cuore Don Calabria di Negrar
Not applicable
170
Negrar
2023-05-22
Recruiting
IRCCS Sacro Cuore Don Calabria di Negrar
Not applicable
184
Negrar
2023-04-03
Active, closed
Novartis Pharmaceuticals
Phase 4
240
Ancona, Torino, Negrar, Verona
2023-03-28
Active, closed
ABTECT - Maintenance
NCT05535946Ulcerative Colitis
DrugObefazimod
Abivax S.A.
Phase 3
1,116
San Giovanni Rotondo, Rho, Rozzano, San Donato Milanese, Negrar, Alessandria, Bologna, Brescia
2023-01-16
Active, closed
Janssen Research & Development, LLC
Phase 2
577
Bari, Catania, Messina, Milan, Monserrato, Monza, Negrar, Palermo
2022-09-19
Active, closed
AbbVie
Observational
785
Castellana Grotte, Rozzano, Milan, Naples, Rome, Negrar, Palermo, Pisa
2022-08-15
Active, closed
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
NCT05407636AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
DrugsEylea·Aflibercept
AbbVie
Phase 3
735
Cona, Milan, Naples, Rome, Negrar, Bari, Chieti, Udine
2022-01-13
Active, closed
AstraZeneca
Phase 3
927
Bologna, Candiolo, Livorno, Milan, Naples, Negrar, Padova, Roma
2021-10-25
Active, closed
Fondazione Ricerca Traslazionale
Phase 2
105
Meldola, Saronno, Legnago, Negrar, Civitavecchia, Florence, Messina, Novara
2021-10-12
Active, closed
AbbVie
Phase 3
527
Bologna, Genoa, Milan, Rho, Rome, Negrar, Cagliari, Palermo
2020-09-30
Recruiting
IRCCS Sacro Cuore Don Calabria di Negrar
Observational
60,000
Negrar
2019-10-30
Active, closed
Janssen Research & Development, LLC
Phase 2/3
1,064
Bologna, Milan, Negrar, Padova, Palermo, Rho, Roma, Rozzano
2019-09-26
Recruiting
European Organisation for Research and Treatment of Cancer - EORTC
Observational
2,000
Acquaviva delle Fonti, Arezzo, Brescia, Florence, Milan, Negrar, Pavia, Perugia
2019-06-24
Recruiting
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
NCT04075305Oncology, Breast Cancer, Prostate Cancer, Gynecologic Cancer
UMC Utrecht
Observational
8,000
Brescia, Negrar
2019-02-01
Active, closed
Fondazione Michelangelo
Phase 3
650
Bergamo, Brindisi, Faenza, Genova, Meldola, Milan, Modena, Negrar
2018-09-07
Active, closed
AbbVie
Phase 3
1,242
Genoa, Rozzano, Milan, Rho, Rome, Negrar, Bologna, Catania
2018-08-28
Recruiting
Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria
Not applicable
340
Alessandria, Forlì, Camposampiero, Negrar, Acquaviva delle Fonti, Biella, Brescia, Cremona
2018-06-05
Active, closed
AbbVie
Phase 3
1,336
Torrette, Genoa, Rozzano, Milan, Rho, Rome, Florence, Negrar
2018-04-09
Active, closed
AbbVie
Phase 3
747
Bologna, Rozzano, Milan, Rome, Negrar, Catania, Catanzaro, Genova
2018-03-21
Active, closed
AbbVie
Phase 3
950
Bologna, Rozzano, Milan, Rho, Rome, Negrar, Palermo
2017-01-31
Active, closed
Eli Lilly and Company
Phase 3
493
Brindisi, Cona, Genoa, Candiolo, Prato, Negrar, Bergamo, Bologna
2014-11-06
Rows per page Showing 1–57 of 57
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Italian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 14 November 2026. https://priyalifescience.com/clinical-trials-italy/city/negrar

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Italy and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,788 studies in total at the last sync on 13 Nov 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 57 of those studies with a site in Negrar.

How many clinical trials are recruiting in Negrar?

31 of the 57 studies on this page are recruiting new participants as of the 13 Nov 2026, 03:19 UTC sync. A further 2 have not yet opened recruitment, 23 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Negrar), 57 studies
PhaseStudiesRecruitingShare
Phase 319633.3%
Not applicable171429.8%
Phase 210517.5%
Observational9615.8%
Phase 2/3101.8%
Phase 4101.8%

Most active sponsors

Lead sponsors with the most studies (Negrar)
Lead sponsorStudiesRecruiting
IRCCS Sacro Cuore Don Calabria di Negrar1714
AbbVie91
Janssen Research & Development, LLC42
Eli Lilly and Company32
Abivax S.A.21
AstraZeneca21
European Organisation for Research and Treatment of Cancer - EORTC22
Hoffmann-La Roche21
Novartis Pharmaceuticals21
Alfasigma S.p.A.10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.